论文部分内容阅读
目的探讨P-cadherin和34βE12在乳腺柱状细胞病变中的表达与意义。方法采用En Vision免疫组化染色法检测P-cadherin和34βE12在乳腺柱状细胞改变和增生(columnar cell changes and hyperplasia,CCCH)及平坦型上皮非典型增生(flat epithelial atypia,FEA)中的表达水平,评价两者在乳腺柱状细胞病变(columnar cell lesions,CCLs)中的诊断意义。结果P-cadherin在CCCH中阳性表达为96.0%(72/75),在FEA中阳性表达为45.5%(5/11),表达差异具有统计学意义(P<0.05);34βE12在CCCH中阳性表达为77.3%(58/75),在FEA中阳性表达为27.3%(3/11),表达差异具有统计学意义(P<0.05)。结论 P-cadherin和34βE12有助于CCCH与FEA的临床病理诊断。
Objective To investigate the expression and significance of P-cadherin and 34βE12 in breast cell disease. Methods The expression of P-cadherin and 34βE12 in columnar cell changes and hyperplasia (CCCH) and flat epithelial atypia (FEA) were detected by En Vision immunohistochemical staining. To evaluate the diagnostic significance of the two in the diagnosis of columnar cell lesions (CCLs). Results The positive expression of P-cadherin in CCCH was 96.0% (72/75) and in FEA was 45.5% (5/11), the difference was statistically significant (P <0.05). The expression of 34βE12 was positive in CCCH (77.3%, 58/75). The positive expression in FEA was 27.3% (3/11), the difference was statistically significant (P <0.05). Conclusion P-cadherin and 34βE12 contribute to the clinicopathological diagnosis of CCCH and FEA.